UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 6, 2013

Sucampo Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-33609	30-0520478
(State or Other Juris-	(Commission	(IRS Employer
diction of Incorporation)	File Number)	Identification No.)
4520 East-West Highway, 3 rd Floor Bethesda, Maryland		20814
(Address of Principal Executive Offices)		(Zip Code)
Registrant's	telephone number, including area code: (301) 961-3	3400
(Former Na	ame or Former Address, if Changed Since Last Repo	ort)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

On June 6, 2013, Sucampo Pharmaceuticals, Inc. ("Company") will make a corporate update presentation via webcast at an investor conference in New York City, NY at the Jefferies 2013 Global Healthcare Conference. During June 10-11, 2013, the Company will make corporate update presentations at one-on-one meetings with analysts and investors in New York, New Jersey and Connecticut. All meetings will include written communications comprised of slides. The slides are being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 to this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 The corporate update presentation slides dated June 6, 2013.

SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 6, 2013

SUCAMPO PHARMACEUTICALS, INC.

By: /s/ Thomas J. Knapp Name: Thomas J. Knapp

Title: EVP, Chief Legal Officer and Corporate Secretary



Jefferies 2013 Global Healthcare Conference

Sucampo Pharmaceuticals, Inc. Corporate Update

Cary Claiborne, Chief Financial Officer

June 6, 2013



Forward-Looking Statements

This presentation contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; Sucampo's ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the US and internationally and the exposure to litigation and/or regulatory actions.

No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Sucampo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect Sucampo's business, particularly those mentioned in the risk factors and cautionary statements in Sucampo's most recent Form 8-K and 10-K, which Sucampo incorporates by reference.



Sucampo Snapshot: Prostone Pioneers

Sucampo's Mission:

To develop and commercialize prostone-based medicines to meet the major unmet medical needs of patients on a global basis

- · Commercial-stage, global biopharmaceutical company
- · 2 FDA-approved drugs based on our proprietary prostone technology
 - AMITIZA[®] (lubiprostone) in gastroenterology
 - Approved for chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), and opioid-induced constipation (OIC)
 - · RESCULA® (unoprostone isopropyl) in ophthalmics
 - Approved for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension

Prostone pioneers

Therapeutic potential 1st identified by Sucampo's founders, Dr. Ryuji Ueno and Dr. Sachiko Kuno

® Registered trademark of Sucampo



Sucampo Has Pioneered the Field of Prostones


Sucampo is the only company developing and commercializing prostone compounds globally

- Prostones:
 - Functional fatty acids naturally occuring in the human body
 - · Selective ion-channel activators
 - Physiological mediators of restoration of cellular homeostasis and tissue regeneration
- Clinical safety profile of prostones is well-tolerated, as demonstrated by the clinical safety record of AMITIZA and RESCULA
- Clinical potential of prostones is broad and applicable to various therapeutic fields beyond those already established




See Reference 1

Proprietary Platform Technology: Sucampo's Prostones are Highly Potent Ion-Channel Activators



Global AMITIZA Approvals and Regulatory Filings



Sucampo: Leader in Gastroenterology with Three Approved Indications for AMITIZA

CIC

- CIC affects ~14%-16%^{2,3} and CIC accounts for 92,000 hospitalizations/yr in US⁴
- IBS-C
 - IBS-C affects ~5% of adult population globally⁵
 - Patients with IBS consume >50% more healthcare resources than those without IBS⁶ and the direct and indirect costs of IBS care in the US equal \$20 billion/yr⁵
 - Severe constipation is associated with increased cardiovascular risk in women^{7,8}
- OIC
 - More than 230M prescriptions for opioid use in the U.S. annually⁹; OIC affects around 4.5M of these patients (2.5M are moderate to severe)¹⁰
 - Constipation is the most common reason for discontinuation of opioid therapy and longest lasting common side effect of chronic opioids⁹
 - · Currently no other approved oral prescription products on the market¹¹
 - Increases cost of care and decreases HRQOL⁹

See References 2-11



AMITIZA US

OIC indication approved in April 2013

- Priority review for first and only medicine for the treatment of OIC in adults with chronic, non-cancer pain
- \$10M milestone payment received
- Partner Takeda's reps began selling week of May 13
- Strategy to build awareness that AMITIZA is the first and only medicine for OIC among PCPs and pain specialists

Strong AMITIZA YOY Growth

- Q1 TRx growth: +4% YoY
- Q1 net sales increase: +7% YoY to \$64.9M
- Growth continuing: TRx +6% YoY for April
- New competitor is creating more awareness and growing the market


Over 7M prescriptions over 7 years

· Expect to rise substantially





AMITIZA US OIC Launch: Build on Strengths and Heritage



Strategy to Grow AMITIZA


Target	Goal
PCPs who already write AMITIZA	
Pain Specialists	+OIC
Gls	
Target	Goal

PCP Non-Writers	+CIC +IBS-C
	+OIC



Competitive Landscape

EXPECT NO MARKET CHALLENGE FOR AMITIZA USE FOR OIC NON-CANCER PATIENTS FOR UP TO 2 YEARS



AMITIZA Globally

Japan	 First-ever prescription medicine approved for chronic constipation All launch metrics have been surpassed: revenue and patient numbers tracking above expectation Sucampo recorded \$2.2M of product sales revenue in Q1, double our internal forecast
Europe	 Initiated NICE endorsement process in UK following CIC approval Initiated MRP (CIC) in additional EU markets OIC indication filed in both Switzerland and UK Commenced active marketing (CIC) in Switzerland

We have also received expressions of interest from potential partners for AMITIZA for new indications and new territories, including Europe, Asia and emerging markets




Sucampo: Emerging Player in Ophthalmics

- Glaucoma is age-related and the second leading cause of bilateral blindness worldwide; will affect an estimated 79.6M people worldwide by 2020¹³
 - Reduction in intra-ocular pressure (IOP) is currently the only modifiable risk factor for patients with glaucoma and ocular hypertension¹³
- Compliance and adherence are unmet needs
 - 50% of new patients drop off therapy within one year of initiation¹⁴
 - Hyperemia is the #1 reason for discontinuation of prostaglandins, often chosen as first line therapy¹⁵





See References 1, 13-15




- Primary Open Angle Glaucoma / Ocular Hypertension market has unmet needs
- RESCULA offers an alternate route to IOP reduction the strength of RESCULA is its safety and tolerability profile
- · RESCULA will have a competitive share of voice



See References 1, 16


US Market: 30M Rxs (and Growing) for IOP Lowering Medications

- 2.2M people affected by Open Angle Glaucoma¹⁷
 - Projected to grow to 3.4M by 2020 due to aging population¹⁷
- Additional 3-6M patients with Ocular Hypertension¹⁸
- ~\$2B: US sales volume (2012)¹⁹ and ~\$1B: Japan sales volume (2011)¹




Unique Considerations for Glaucoma Treatment in Elderly Patients

- More than 11M Americans are ≥ 80 years of age²⁰
 - Age is an independent risk factor for glaucoma¹⁷
- Elderly patients generally have greater susceptibility to the systemic adverse effects of glaucoma medications^{21,22}



Prostaglandin Analogs Followed by Beta Blockers are Top Rx Categories



RESCULA Provides an Alternate Route to IOP Reduction

- Believed to reduce elevated IOP by increasing the outflow of aqueous humor through the trabecular meshwork via BK channel activation
- · A prostone, not a prostaglandin analog
- Should be considered when systemic and/or ocular side effects are a concern:
 - Effective at lowering IOP throughout the day
 and over the long-term



- Established ocular side effect profile: RESCULA and timolol maleate both generally well tolerated in clinical studies with similar incidence of hyperemia
- Excellent systemic safety profile with no deleterious effects on CV or pulmonary function in clinical studies
- No labeled drug-drug interactions

See References 16, 27



RESCULA Launch Update

- Positive feedback and significant progress
 - Efforts focused on ophthalmologists and optometrists .
 - · More than 19,000+ calls have already been made
 - Over 78,000 samples have been shipped
 - Expect sales to increase in 2H
- Aggressively pursuing managed care coverage for RESCULA .
 - Over 100 face to face meetings with plans and PBMs ٠
 - Strong reception from plans
- Route to Savings[™]: Committed to Patient Access •
 - 33% of RESCULA TRxs going through RTS Program •
 - Commercial co-pay reductions seen from \$55 \$18 •










Sucampo's Clinical Pipeline and Product Development



Key Facts


Trading Symbol	SCMP (NASDAQ)
Corporate Headquarters	Bethesda, MD
Stock Price (06-03-13), 52-Week Range	\$8.48, \$10.48 to \$3.78
Shares Outstanding (06-03-13)	42.3 M (1 class of common stock)
Daily Volume (90-day average)	229,661
Market Capitalization (06-03-13)	\$358.5M
Debt (03-31-13)	\$62.5M
Cash & Equivalents (03-31-13)	\$95.8M
Enterprise Value (06-03-13)	\$325.1M
Full-time Employees (06-03-13)	117
Fiscal Year Ends	December 31
Accounting Firm	PricewaterhouseCoopers LLP



Q1 2013 Financial Highlights



AMITIZA US Global Japan EU	US	 Obtain approval of OIC sNDA: Q2 2013 \$10M milestone payment upon first OIC sale Achieve FPFV in Pediatric P3 trial by H2 2013
	Pursue strategic alliances; new AMITIZA indications / territories	
	Grow sales in Japan in 2013	
	EU	 Submit for regulatory approval of OIC in Switzerland and UK by Q1 2013 Begin active marketing in Switzerland for CIC Seek NICE endorsement for CIC and OIC, and make AMITIZA available in UK for CIC Use MHRA approval to seek expansion of CIC indication to other EU markets via MRP
RESCULA	US	✓ Launch: Q1 2013
Pipeline	Cobiprostone	 Complete oral mucositis P1A trial: Q2 2013 Initiate P1B/2A trial in oral mucositis: Q4 2013
	SPI-017	Complete spinal stenosis P2A trial: Q4 2013





Terms of Sucampo's AMITIZA Agreements

Takeda Agreement

- · Takeda shall promote, market, and sell AMITIZA in US and Canada
- Sucampo's tiered royalty rate: 18%-26% of annual net sales
- Sucampo earned \$20M in upfront and \$130M in development milestone payments as of 03/31/13
 - Sucampo received \$10M milestone payment following the first OIC sale
- Sucampo received \$109M in reimbursement for R&D expenses from Takeda as of 03/31/13
- Abbott Japan Agreement
 - Abbott Japan shall promote, market, and sell AMITIZA in Japan
 - Sucampo will sell product to Abbott Japan at discount to Abbott Japan's approved reimbursement price
 - Sucampo earned \$10M in upfront and \$27.5M in development milestone payments as of 03/31/13



Substantial Abdominal Pain Improvement in IBS-C Patients Reporting at Least Severe Abdominal Pain at Baseline*

% Improvement	Placebo BID (n = 94)	Lubiprostone 8 µg BID (n = 183)	<i>P</i> Value⁺
≥10	53.9%	61.9%	<0.0001
≥20	40.1%	49.6%	<0.0001
≥ 30	24.2%	35.1%	<0.0001
≥40	14.5%	23.7%	<0.0001
≥50	9.4%	16.7%	<0.0001
≥60	4.7%	12.7%	<0.0001


"LOCF analysis; †P value from CMH test. See Reference 28



Positive Long-term Treatment Response: Phase 3 Studies of AMITIZA 8µg BID in IBS-C



Overall Spontaneous Bowel Movement ("SBM") Response in OIC Patients



AMITIZA Intellectual Property

- AMITIZA has a robust patent estate
 - · Latest patents expire in 2027
- Paragraph IV certification notice letter to Sucampo received on January 2, 2013 regarding ANDA submitted to FDA by Anchen Pharmaceuticals
 - Notice letter alleges AMITIZA's composition, method of use, and/or formulation patents are invalid, unenforceable, and/or will not be infringed by Anchen's manufacture, use or sale of the product described in its ANDA.
- On February 8, 2013 Sucampo announced it had filed a patent infringement lawsuit against Anchen and Par Pharmaceuticals
 - · Sucampo is joined by Takeda and R-Tech Ueno in the lawsuit

Hatch-Waxman Act provides that a federal court lawsuit will preclude FDA from approving ANDA until the earlier of 30 months or a district court decision finding AMITIZA's patents invalid



Issued Lubiprostone Patents

US Patent No.	Expires	Type of Patent
5,284,858	2014	Composition of matter (drug substance)
6,414,016	2020	Therapeutic use (treating constipation)
6,583,174	2020	Composition of matter (drug product)
6,982,283	2022	Therapeutic use (treating OIC)
7,064,148	2022	Therapeutic use (treating constipation)
7,417,067	2020	Composition of matter (drug product)
7,795,312	2024	Therapeutic use (treating IBS)
8,026,393	2027	Composition of matter (drug product)
8,071,613	2020	Therapeutic use (treating constipation)
8,088,934	2021	Composition of matter (drug substance)
8,097,649	2020	Composition of matter (drug product)
8,097,653	2022	Therapeutic use (treating constipation)
8,114,890	2020	Composition of matter (drug product)
8,338,639	2027	Composition of matter (drug product)
8,389,542	2022	Composition of matter (drug product) and therapeutic use (treating constipation)

*For Orange Book-listed patents concerning lubiprostone, see for example: <u>http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=021908&Product_No=001&table1=OB_Rx</u> or

http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl No=021908&Product No=002&table1=OB Rx



Issued Lubiprostone Patents (cont'd)

Japanese		
Patent No.	Expires	Type of Patent
4,332,316	2023	Composition of matter (drug substance)
4,332,353	2022	Therapeutic use (treating OIC)
4,684,334	2023	Therapeutic use (treating constipation)
4,783,794	2028	Composition of matter (drug product)
4,786,866	2023	Therapeutic use (treating constipation)
4,852,229	2023	Therapeutic use (treating constipation)
4,889,219	2024	Therapeutic use (treating IBS)
European		
Patent No.	Expires	Type of Patent
1,220,849	2020	Composition of matter (drug product)
1,315,485	2021	Therapeutic use (treating constipation)
1,392,318	2022	Therapeutic use (treating OIC)
1,426,361	2020	Composition of matter (drug substance)
1,443,938	2022	Therapeutic use (treating constipation)



Issued Unoprostone Isopropyl Patents

US Patent No.	Expires	Type of Patent
6,770,675	2018	Composition of matter (drug product) and therapeutic use
		(treating ocular hypertension)
6,458,836	2021	Therapeutic use (treating ocular hypertension and glaucoma)

*For Orange Book-listed patents concerning unoprostone isopropyl, see for example: <u>http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=021214&Product_No=001&table1=OB_Rx</u>



References

- 1. Sucampo data on file.
- 2. Suares et al. Am J Gastroenterol. 2011
- 3. Kantar Health Epi database http://epidb.khapps.jp
- 4. Lembo et al. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 2010
- 5. Saito et al. Am J Gastroenterol. 2002
- 6. Hulisz D. J Manag Care Pharm. 2004
- 7. Salmoirago-Blotcher et al. Am J Med. 2011
- 8. Talley et al. Am J Gastroenterol. 2001
- Manchikanti L, et al. Pain Physician. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance. 2012 Jul;15(3 Suppl):S67-116.
- 10. Clearview Analysis 2008
- 11. Internal Research
- 12. AMITIZA Physician ATU W11 2013
- 13. Quigley et al. Br J Ophthalmol 2006 Mar;90(3):252-7
- Fain JM et al. A multicenter, retrospective chart review study comparing index therapy change rates in open-angle glaucoma or ocular hypertension patients newly treated with latanoprost or travoprost-Z monotherapy. BMC Ophthalmol. 2011 Jun 13;11(1):13. doi: 10.1186/1471-2415-11-13.
- 15. Zimmerman TJ et al. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther. 2009 Apr;25(2):145-52. doi: 10.1089/jop.2008.0072.
- 16. RESCULA Package Insert
- 17. American Academy of Ophthalmology Glaucoma Panel. Preferred Practice Pattern® guideline: Primary open-angle glaucoma. 2010
- Kass MA et al. Arch Ophthalmol. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. 2002 Jun;120(6):701-13; discussion 829-30.
- 19. Based on Dec 2009 Nov 2012 IMS NSP data
- 20. Based on Dec 2009 Nov 2012 MATTY IMS NPA data



References (cont'd)

- 21. American Academy of Ophthalmology Glaucoma Basic and Clinical Science Course 2012-2013
- 22. US Census Bureau The Older Population: 2010 (November 2011)
- 23. Kaiserman I et al. Topical beta blockers in asthmatic patients-is it safe? Curr Eye Res. 2009 Jul;34(7):517-22.
- 24. Based on US Census Bureau data from May 2010 and November 2011 The Older Population: 2010 (November 2011) & US Census Bureau THE NEXT FOUR DECADES The Older Population in the United States: 2010 to 2050 (May 2010)
- 25. Gottfredsdottir MS et al. Physicians' guide to interactions between glaucoma and systemic medications. J Glaucoma. 1997 Dec/6(6):377-83.
- 26. Based on Dec 2011- Nov 2012 MATTY IMS NPA data
- 27. RESCULA CVA
- 28. Joswick et al. Digestive Disease Week, 2012
- 29. AMITIZA Package Insert

AMITIZA is a registered trademark of Sucampo AG. The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG.

